A mathematical model for targeting chemicals to tissues by exploiting complex degradation

Biology Direct

Volumn 6, Issue , 2011, Pages

  Gardiner, Bruce S ^a   Zhang, Lihai ^b   Smith, David W ^a   Pivonka, Peter ^a   Grodzinsky, Alan J ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c USA   (United States)

Author keywords

Insulin like growth factor (igf); Mathematical model; Prodrug; Proteases; Solute transport; Tissue

Indexed keywords

PRODRUG; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ANIMAL; ARTICLE; BIOLOGY; CARTILAGE; CELL HYPOXIA; CHEMICAL MODEL; COMPUTER SIMULATION; DIFFUSION; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PROTEIN TRANSPORT;

ANIMALS; CARTILAGE; CELL HYPOXIA; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DIFFUSION; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MODELS, CHEMICAL; NEOPLASMS; PRODRUGS; PROTEIN TRANSPORT;

EID: 80053174918     PISSN: None     EISSN: 17456150     Source Type: Journal    
DOI: 10.1186/1745-6150-6-46     Document Type: Article

References (20)

1. Zhang L, Gardiner BS, Smith DW, Pivonka P, Grodzinsky AJ. On the role of diffusible binding partners in modulating the transport and concentration of proteins in tissues. J Theor Biol 2010, 263(1):20-29. 10.1016/j.jtbi.2009.11.023, 20005880.
2. Cohick WS, Clemmons DR. The insulin-like growth factors. Annual Review of Physiology 1993, 55:131-153. 10.1146/annurev.ph.55.030193.001023, 8466170.
3. Froesch ER, Hussain MA, Schmid C, Zapf J. Insulin-like growth factor I: Physiology, metabolic effects and clinical uses. Diabetes/Metabolism Reviews 1996, 12(3):195-215. 10.1002/(SICI)1099-0895(199610)12:3<195::AID-DMR164>3.0.CO;2-G, 8959385.
4. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. American Journal of Physiology - Endocrinology and Metabolism
5. Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends in Endocrinology and Metabolism 2003, 14:176-181. 10.1016/S1043-2760(03)00049-3, 12714278.
6. Bach RS, Norton LA, Headey SJ. IGF-binding proteins - the pieces are falling into place. Trends in Endocrinology and Metabolism 2005, 16:228-234. 10.1016/j.tem.2005.05.005, 15935690.
7. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995, 16:3-34.
8. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via igf-dependent and - independent mechanisms. Journal of Endocrinology 2002, 175:19-31. 10.1677/joe.0.1750019, 12379487.
9. Fowlkes JL, Serra DM, Nagase H, Thrailkill KM. Mmps are IGFBP-degrading proteinases: Implications for cell proliferation and tissue growth. Annals of the New York Academy of Sciences 1999, 878:696-699. 10.1111/j.1749-6632.1999.tb07765.x, 10415811.
10. Minchinton AI, Tannock IF. Drug penetration into solid tumours. Nature Reviews Cancer 2006, 6:583-592. 10.1038/nrc1893, 16862189.
11. Grief AD, Richardson G. Mathematical modeling of magnetically targeted drug delivery. Journal of Magnetism and Magnetic Materials 2005, 293:455-463.
12. McBain SC, Yiu HHP, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 2008, 3(2):169-180. 2527670, 18686777.
13. Owen MR, Byrne HM, Lewis CE. Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J Theor Biol 2004, 226(4):377-391. 10.1016/j.jtbi.2003.09.004, 14759644.
14. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 2004, 4:437-447. 10.1038/nrc1367, 15170446.
15. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003, 63:5970-5977.
16. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culutre model. Cancer Chemother Pharmacol 1999, 43:213-220. 10.1007/s002800050886, 9923551.
17. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tripazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (trog 02.02, headstart): A phase iii trial of the transtasman radiation oncology group. Journal of Clinical Oncology 2010, 28:2989-2995. 10.1200/JCO.2009.27.4449, 20479425.
18. Barta E, Maroudas A. A theoretical study of the distribution of insulin-like growth factor in human articular cartilage. J Theor Biol 2006, 241:628-638. 10.1016/j.jtbi.2006.01.004, 16494900.
19. Breward CJW, Byrne HM, Lewis CE. Modelling the interactions between tumour cells and a blood vessel in a microenvironment within a vascular tumour. Euro J Appl Math 2001, 12:529-556.
20. Fowkes ND, Mahony JJ. An introdution to mathematical modelling 1994, JohnWiley & Sons.